



Crossject

Supergenerics / France

Success of the capital increase

Latest - 21/12/2018

Fact

Crossject has announced that the c.€4m capital increase had been subscribed with, among others, c. 1,656k shares by Gemmes Venture (the group's historic shareholder, which now controls 30.6% of the share capital) out of a total of c.3.4m new shares. The new number of shares stands at 13.6m and new shares will be listed as from 28 December.

Impact

The capital increase was already included in our numbers. We will only adjust them to account for the conversion of warrants since September that led to a high number of shares pre capital increase.



Fabrice FARIGOULE
pharma@alphavalue.eu
 +33 (0) 1 70 61 10 50
cs.alphavalue.com

AlphaValue is contracted by Crossject to provide equity research on Crossject, using AlphaValue's unique and transparent methods and procedures. Target price and opinion are thus exclusively determined by those methods and procedures.

Buy	Upside: 785%
Target Price (6 months)	€ 11.1
Share Price	€ 1.25
Market Cap. €M	11.6
Price Momentum	UNFAVORABLE
Extremes 12Months	1.19 ▶ 4.65
Bloomberg	ALCJ FP Equity
Reuters	ALCJ.PA



[Download Full Analysis](#)
[Company Page](#)


PERF	1w	1m	3m	12m
Crossject	-3.85%	-0.71%	-55.5%	-68.5%
Pharma	-3.42%	-3.00%	-0.84%	2.66%
STOXX 600	-3.67%	-4.12%	-12.0%	-13.3%

Last updated: 29/11/2018	12/16A	12/17A	12/18E	12/19E
Adjusted P/E (x)	-7.40	-5.28	-1.63	-2.34
Dividend yield (%)	0.00	0.00	0.00	0.00
EV/EBITDA(R) (x)	-8.89	-6.57	-1.07	-2.09
Adjusted EPS (€)	-0.98	-0.97	-0.76	-0.53
Growth in EPS (%)	n/a	n/a	n/a	n/a
Dividend (€)	0.00	0.00	0.00	0.00
Sales (€M)	1.43	4.14	4.00	4.01
EBIT margin (%)	0.00	0.00	0.00	0.00
Attributable net profit (€M)	-6.66	-7.61	-8.12	-6.72
ROE (after tax) (%)	-88.4	-123	-120	-158
Gearing (%)	-62.3	-42.6	-58.4	-387

[Company Valuation](#) - [Company Financials](#)

Sales by Geography



■ Americas (55.0%)
■ Europe (25.0%)
■ Asia (20.0%)

Consolidated P&L Accounts

		12/17A	12/18E	12/19E
Sales	€M	4.14	4.00	4.01
Change in sales	%	190	-3.44	0.25
Change in staff costs	%	33.0	23.7	11.3
EBITDA	€M	-6.35	-8.82	-6.73
EBITDA(R) margin	%	-153	-221	-168
Depreciation	€M	-2.28	-3.00	-3.00
Underlying operating profit	€M	-8.62	-11.8	-9.73
Operating profit (EBIT)	€M	-8.62	-11.8	-9.73
Net financial expense	€M	0.16	-0.30	-0.30
of which related to pensions	€M		0.00	0.00
Exceptional items & other	€M	-0.28	0.00	0.00
Corporate tax	€M	1.13	4.00	3.31
Equity associates	€M			
Minority interests	€M			
Adjusted attributable net profit	€M	-7.61	-8.12	-6.72
NOPAT	€M	-6.03	-8.28	-6.81

Cashflow Statement

		12/17A	12/18E	12/19E
EBITDA	€M	-6.35	-8.82	-6.73
Change in WCR	€M	0.94	0.53	0.72
Actual div. received from equity holdi...	€M	0.00	0.00	0.00
Paid taxes	€M	0.00	4.00	3.31
Exceptional items	€M	0.00	0.00	0.00
Other operating cash flows	€M	0.00	0.00	0.00
Total operating cash flows	€M	-5.41	-4.29	-2.70
Capital expenditure	€M	-4.25	-4.05	-1.60
Total investment flows	€M	-4.25	-4.05	-1.60
Net interest expense	€M	0.16	-0.30	-0.30
Dividends (parent company)	€M			
Dividends to minorities interests	€M	0.00	0.00	0.00
New shareholders' equity	€M	7.41	9.30	0.00
Total financial flows	€M	9.40	11.4	3.46
Change in cash position	€M	-0.25	3.05	-0.84
Free cash flow (pre div.)	€M	-9.49	-8.64	-4.60

Per Share Data

		12/17A	12/18E	12/19E
No. of shares net of treas. stock (year...	Mio	8.64	12.5	12.5
Number of diluted shares (average)	Mio	7.87	10.6	12.6
Benchmark EPS	€	-0.97	-0.76	-0.53
Restated NAV per share	€			
Net dividend per share	€	0.00	0.00	0.00

Valuation Summary

Benchmarks	Value	Weight	Largest comparables
DCF	€ 14.8	40%	■ Faes Farma
NAV/SOTP per share	€ 12.7	40%	■ Hikma Pharmaceuti...
P/E	€ 0.63	5%	■ Ipsen
EV/Ebitda	€ 0.00	5%	■ Stada Arzneimittel
P/Book	€ 0.63	5%	■ UCB
Dividend Yield	€ 0.00	5%	
TARGET PRICE	€ 11.1	100%	

NAV/SOTP Calculation

Balance Sheet

		12/17A	12/18E	12/19E
Goodwill	€M	0.00	0.00	0.00
Total intangible	€M	4.06	3.31	2.56
Tangible fixed assets	€M	6.52	8.32	7.67
Financial fixed assets	€M	0.10	0.10	0.10
WCR	€M	-3.11	-3.64	-4.36
Other assets	€M	2.33	2.57	2.81
Total assets (net of short term liab.)	€M	9.94	10.7	8.82
Ordinary shareholders' equity	€M	6.09	7.50	1.02
Quasi Equity & Preferred	€M			
Minority interests	€M			
Provisions for pensions	€M	0.00	0.00	0.00
Other provisions for risks and liabilities	€M	0.09	0.09	0.09
Total provisions for risks and liabilities	€M	0.09	0.09	0.09
Tax liabilities	€M	0.00	0.00	0.00
Other liabilities	€M	6.26	9.36	9.36
Net debt (cash)	€M	-2.50	-6.26	-1.66
Total liab. and shareholders' equity	€M	9.94	10.7	8.82

Capital Employed

		12/17A	12/18E	12/19E
Capital employed after depreciation	€M	7.57	8.09	5.97

Profits & Risks Ratios

		12/17A	12/18E	12/19E
ROE (after tax)	%	-123	-120	-158
ROCE	%	-79.8	-102	-114
Gearing (at book value)	%	-42.6	-58.4	-387
Adj. Net debt/EBITDA(R)	x	0.39	0.71	0.25
Interest cover (x)	x	53.9	-39.4	-32.4

Valuation Ratios

		12/17A	12/18E	12/19E
Reference P/E (benchmark)	x	-5.28	-1.63	-2.34
Free cash flow yield	%	-21.5	-55.3	-29.4
P/Book	x	7.24	2.08	15.3
Dividend yield	%	0.00	0.00	0.00

EV Calculation

		12/17A	12/18E	12/19E
Market cap	€M	44.1	15.6	15.6
+ Provisions	€M	0.09	0.09	0.09
+ Unrecognised actuarial losses/(gains)	€M	0.00	0.00	0.00
+ Net debt at year end	€M	-2.50	-6.26	-1.66
+ Leases debt equivalent	€M	0.00	0.00	0.00
- Financial fixed assets (fair value)	€M			
+ Minority interests (fair value)	€M			
= EV	€M	41.7	9.46	14.1
EV/EBITDA(R)	x	-6.57	-1.07	-2.09
EV/Sales	x	10.1	2.37	3.51

Analyst : Fabrice Farigoule, Changes to Forecasts : 29/11/2018.